OS Therapies Past Earnings Performance
Past criteria checks 0/6
OS Therapies's earnings have been declining at an average annual rate of -7.9%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-7.9%
Earnings growth rate
-1.6%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How OS Therapies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -8 | 1 | 3 |
31 Dec 23 | 0 | -8 | 1 | 3 |
30 Sep 23 | 0 | -9 | 2 | 3 |
31 Mar 23 | 0 | -7 | 1 | 3 |
31 Dec 22 | 0 | -6 | 1 | 3 |
30 Sep 22 | 0 | -6 | 1 | 3 |
31 Dec 21 | 0 | -8 | 2 | 2 |
Quality Earnings: OSTX is currently unprofitable.
Growing Profit Margin: OSTX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OSTX is unprofitable, and losses have increased over the past 5 years at a rate of 7.9% per year.
Accelerating Growth: Unable to compare OSTX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OSTX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: OSTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.